FDA Approves New Treatment for
Advanced Head and Neck Cancer
The Food and Drug Administration
(FDA) today approved
Taxotere (docetaxel) Injection Concentrate
for use in combination with cisplatin
and fluorouracil prior to radiotherapy
for the treatment of patients
with inoperable, locally advanced squamous cell
carcinoma of the head and neck (SCCHN).
This disease represents approximately
3 percent of all new cancer cases
in the United States.
紫杉萜被FDA许可联合顺铂、氟脲嘧啶用于治疗头颈癌。
"Today's approval will provide prescribers
with a new treatment option that has been
shown to help slow the spread of the disease
and prolong patients' survival,
" said Steven Galson, M.D., director
of FDA's Center for Drug Evaluation and Research.
